INTELLIGENT BIO SOLUTIONS INC. — Director's Dealing 2023

Jul 11, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INTELLIGENT BIO SOLUTIONS INC. (INBS)
CIK: 0001725430
Period of Report: 2023-05-10

Reporting Person: Sakiris Spiro Kevin (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-10	Common Stock	C	2399	$5.80	Acquired	4745	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-10	Series D Convertible Preferred Stock	$	C	15993	Disposed		Common Stock (2399)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3765	Direct

Footnotes

F1: On February 9, 2023, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. This Form 4 also corrects the number of securities held directly and indirectly by Mr. Sakiris. Prior to the Reverse Split, each share of Series D Convertible Preferred Stock (the "Preferred Stock") was convertible into 3 shares of common stock. Following the Reverse Split, each share of Preferred Stock was convertible into 0.15 shares of common stock.

F2: Following the Trigger Date (defined below), each share of Preferred Stock was convertible at any time at the option of the holder and without payment of further consideration. The Preferred Stock has no expiration date. The term "Trigger Date" means the earlier to occur of (i) the date that the last of (a) the shareholders approve conversion of the Preferred Stock or (b) the shareholders approve a reverse split of the Issuer's common stock; or (ii) the date which is 60 days following the date on which the common stock is no longer listed on the Nasdaq, the NYSE or the NYSE American. The Issuer's stockholders approved the conversion of the Preferred Stock at a meeting of stockholders on May 8, 2023, and effective as of May 10, 2023, all shares Preferred Stock were converted into common stock.

F3: On December 22, 2022, Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, purchased 15,993 units from the Issuer in a private placement. Each unit consists of one share of Series D Convertible Preferred Stock (valued at $0.87 each (pre- Reverse Split)) and three common stock purchase warrants (collectively valued at $0.35(pre- Reverse Split), or $0.1267 each (pre- Reverse Split)). The purchase price of each unit was $1.25 per unit (pre- Reverse Split).

F4: These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.